News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daxor Corporation (DXR) Announces Sale of BVA-100 Blood Volume Analyzer and Payment of a Dividend


8/3/2012 9:31:32 AM

NEW YORK, NY--(Marketwire - August 03, 2012) -

Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, today announced the sale of a BVA-100 Blood Volume Analyzer. The Hospital that has purchased the machine is located in Arizona and has approximately 270 beds.

Dr. Joseph Feldschuh, The President and Chief Executive Officer of Daxor, said, "This sale is important news for our Company. Regulations issued by Medicare are being implemented in January 2013 which will penalize hospitals who readmit congestive heart failure patients in less than 30 days. We feel that this should provide a major incentive for hospitals to use the BVA-100 Blood Volume Analyzer to treat congestive heart failure patients."

The Board of Directors has approved payment of a dividend of $0.10 per share. The dividend will be paid on Friday, August 24th to shareholders of record on Tuesday, August 14th. In 2011, the Company paid a total dividend of $0.25 per share as follows: $0.15 per share on June 16th and $0.10 per share on November 30th.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.


Daxor Contact Information:
David Frankel
Chief Financial Officer
212-330-8504
dfrankel@daxor.com

Richard Dunn
Director of Operations
212-330-8502
rdunn@daxor.com

Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES